Huntington’s disease involves both genetic and environmental factors that contribute to its progression. This track will delve into the latest research on the disease's molecular mechanisms, examining the roles of protein aggregation, neuronal degeneration, and genetic mutations. Participants will explore advancements in identifying early biomarkers and potential therapies aimed at slowing or halting the disease’s course.
Track 11-1: Genetic Insights into Huntington’s Disease
Track 11-2: Neurodegenerative Mechanisms in Huntington’s Disease
Track 11-3: Cognitive and Psychiatric Complications in Huntington’s Disease
Track 11-4: Approaches to Targeted Treatments
Track 11-5: The Role of Clinical Trials in Huntington’s Disease
This track focuses on translating molecular understanding into therapeutic strategies and improving the diagnostic and treatment landscape for huntington’s disease.
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
